Experience of using ISGTL-2 in patients with DM2 and HIV infection.
Unidad de Medicina Interna, Hospital Costa del Sol, Marbella, Spain.
M Dolores
MD
García de Lucas
Unidad de Medicina Interna, Hospital Costa del Sol, Marbella, Spain. Electronic address: julianos@hcs.es.
Julián
J
Olalla
D018791:CD4 Lymphocyte Count; D000068896:Canagliflozin / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006442:Glycated Hemoglobin / Q000032:analysis; D015658:HIV Infections / Q000150:complications*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D013030:Spain; D016896:Treatment Outcome; D019562:Viral Load
D000068896:Canagliflozin; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents
Diabetes; HIV; ISGTL2